Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 554

1.

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.

Weiss A, King TA, Hunt KK, Mittendorf EA.

Surg Clin North Am. 2018 Aug;98(4):687-702. doi: 10.1016/j.suc.2018.03.005. Epub 2018 May 21. Review.

PMID:
30005768
2.

Satisfaction and Sustainability in a Surgical Career.

Hunt KK, Wingate HF.

Ann Surg Oncol. 2018 Jul 10. doi: 10.1245/s10434-018-6577-4. [Epub ahead of print] No abstract available.

PMID:
29992496
3.

The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial.

Rosenkranz KM, Ballman K, McCall L, Kubicky C, Cuttino L, Le-Petross H, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC.

Ann Surg Oncol. 2018 Jul 9. doi: 10.1245/s10434-018-6583-6. [Epub ahead of print]

PMID:
29987605
4.

American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation.

DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez-MacGregor M, Shen Y, Kuerer HM, Lucci A.

Ann Surg Oncol. 2018 Jul 9. doi: 10.1245/s10434-018-6580-9. [Epub ahead of print]

PMID:
29987598
5.

Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.

Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC.

Support Care Cancer. 2018 Jul 6. doi: 10.1007/s00520-018-4334-7. [Epub ahead of print]

PMID:
29980907
6.

Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins.

Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS.

Ann Surg Oncol. 2018 Jun 26. doi: 10.1245/s10434-018-6607-2. [Epub ahead of print]

PMID:
29947001
7.

Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.

Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, Fitzal F, Rubio IT, Tiezzi DG, Shin HC, Anderson SJ, Hunt KK, Matsuda N, Ohsumi S, Totomi A, Nilsson C.

Cancer. 2018 Jul 15;124(14):2923-2930. doi: 10.1002/cncr.31518. Epub 2018 May 3.

PMID:
29723396
8.

Nongastrointestinal Stromal Tumor Spindle Cell Sarcomas of the Colon or Rectum.

Ikoma N, Roland CL, Cormier JN, Chiang YJ, Torres KE, Hunt KK, You YN, Feig BW.

Am Surg. 2018 Apr 1;84(4):570-575.

PMID:
29712608
9.

Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement.

Loghavi S, Medeiros LJ, Javadi S, Lin P, Khoury JD, Nastoupil L, Hunt KK, Clemens MW, Miranda RN.

Aesthet Surg J. 2018 Jun 13;38(7). doi: 10.1093/asj/sjy097. No abstract available.

PMID:
29635424
10.

Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit.

Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW.

Ann Surg Oncol. 2018 Aug;25(8):2193-2200. doi: 10.1245/s10434-018-6417-6. Epub 2018 Mar 8.

PMID:
29520652
11.

Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors: A Population-Based Survey Study.

Swanick CW, Lei X, Xu Y, Shen Y, Goodwin NA, Smith GL, Giordano SH, Hunt KK, Jagsi R, Shaitelman SF, Peterson SK, Smith BD.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):882-890. doi: 10.1016/j.ijrobp.2017.11.047. Epub 2017 Dec 9.

PMID:
29485067
12.

Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems for Soft Tissue Sarcoma of the Trunk and Extremities.

Fisher SB, Chiang YJ, Feig BW, Cormier JN, Hunt KK, Torres KE, Roland CL.

Ann Surg Oncol. 2018 May;25(5):1126-1132. doi: 10.1245/s10434-018-6378-9. Epub 2018 Feb 21.

PMID:
29468609
13.

Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy.

Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BW.

J Surg Oncol. 2018 Apr;117(5):879-885. doi: 10.1002/jso.24988. Epub 2018 Feb 15.

PMID:
29448300
14.

Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Le-Petross HT, McCall LM, Hunt KK, Mittendorf EA, Ahrendt GM, Wilke LG, Ballman KV, Boughey JC.

AJR Am J Roentgenol. 2018 Mar;210(3):669-676. doi: 10.2214/AJR.17.18295. Epub 2018 Jan 30.

15.

Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL.

Oncoimmunology. 2017 Oct 31;7(2):e1385689. doi: 10.1080/2162402X.2017.1385689. eCollection 2018.

PMID:
29308306
16.

Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center.

Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW.

J Surg Oncol. 2018 May;117(6):1188-1194. doi: 10.1002/jso.24951. Epub 2017 Dec 11.

PMID:
29228466
17.

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA.

JAMA Oncol. 2018 Feb 1;4(2):203-209. doi: 10.1001/jamaoncol.2017.4298.

PMID:
29222540
18.

Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma.

Keung EZ, Chiang YJ, Voss RK, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL.

Eur J Surg Oncol. 2018 Jan;44(1):170-177. doi: 10.1016/j.ejso.2017.11.014. Epub 2017 Nov 27.

PMID:
29208319
19.

Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma.

Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, Lofts J, Amin MB, Ming Chai S, Morine A, Di Napoli A, Dogan A, Parkash V, Bhagat G, Tritz D, Quesada AE, Pina-Oviedo S, Hu Q, Garcia-Gomez FJ, Jose Borrero J, Horna P, Thakral B, Narbaitz M, Hughes RC 3rd, Yang LJ, Fromm JR, Wu D, Zhang D, Sohani AR, Hunt J, Vadlamani IU, Morgan EA, Ferry JA, Szigeti R, C Tardio J, Granados R, Dertinger S, Offner FA, Pircher A, Hosry J, Young KH, Miranda RN.

Am J Surg Pathol. 2018 Mar;42(3):293-305. doi: 10.1097/PAS.0000000000000985.

PMID:
29194092
20.

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.

Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

PMID:
29180466
21.

Integrating New Knowledge and Surgical Innovation into the Diagnosis and Management of Breast Cancer.

Hunt KK.

Surg Oncol Clin N Am. 2018 Jan;27(1):xv-xvi. doi: 10.1016/j.soc.2017.10.001. No abstract available.

PMID:
29132570
22.

Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.

Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS.

Clin Breast Cancer. 2017 Oct 13. pii: S1526-8209(17)30412-3. doi: 10.1016/j.clbc.2017.10.007. [Epub ahead of print]

PMID:
29100726
23.

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.

Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT.

Ann Oncol. 2017 Oct 1;28(10):2420-2428. doi: 10.1093/annonc/mdx397.

PMID:
28961844
24.

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K.

Clin Cancer Res. 2017 Dec 1;23(23):7288-7300. doi: 10.1158/1078-0432.CCR-17-1544. Epub 2017 Sep 25.

25.

DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes.

Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK.

J Cancer. 2017 Aug 22;8(14):2653-2662. doi: 10.7150/jca.20871. eCollection 2017. Review.

26.

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M.

JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.

27.

Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.

Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA.

Ann Surg Oncol. 2017 Oct;24(10):2925-2934. doi: 10.1245/s10434-017-5958-4. Epub 2017 Aug 1.

PMID:
28766207
28.

Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM.

Ann Surg. 2017 Jul 24. doi: 10.1097/SLA.0000000000002439. [Epub ahead of print]

PMID:
28742682
29.

Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology.

Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK.

Ann Surg Oncol. 2017 Nov;24(12):3502-3509. doi: 10.1245/s10434-017-6009-x. Epub 2017 Jul 19.

PMID:
28726077
30.

Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).

Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK.

Ann Surg. 2017 Oct;266(4):667-676. doi: 10.1097/SLA.0000000000002373.

PMID:
28657941
31.

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.

Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K.

Nat Commun. 2017 Jun 27;8:15916. doi: 10.1038/ncomms15916.

32.

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.

Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK.

Mol Cancer Ther. 2017 Sep;16(9):1751-1764. doi: 10.1158/1535-7163.MCT-17-0040. Epub 2017 Jun 15.

PMID:
28619757
33.

Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer.

Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF.

Breast J. 2018 Jan;24(1):28-34. doi: 10.1111/tbj.12829. Epub 2017 Jun 13.

PMID:
28608612
34.

Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH.

Oncologist. 2017 Nov;22(11):1292-1300. doi: 10.1634/theoncologist.2017-0116. Epub 2017 Jun 7.

PMID:
28592619
35.

Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery.

Ikoma N, Torres KE, Lin HY, Ravi V, Roland CL, Mann GN, Hunt KK, Cormier JN, Feig BW.

J Surg Oncol. 2017 Sep;116(3):313-319. doi: 10.1002/jso.24667. Epub 2017 May 29.

36.

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT.

Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.

PMID:
28549010
37.

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.

Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER.

Ann Oncol. 2017 May 1;28(5):1070-1077. doi: 10.1093/annonc/mdx048.

38.

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.

Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM.

JAMA Surg. 2017 Jul 1;152(7):665-670. doi: 10.1001/jamasurg.2017.0562.

PMID:
28423171
39.

Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation.

Reddy JP, Lei X, Huang SC, Nicklaus KM, Fingeret MC, Shaitelman SF, Hunt KK, Buchholz TA, Merchant F, Markey MK, Smith BD.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):894-902. doi: 10.1016/j.ijrobp.2016.12.021. Epub 2016 Dec 21.

40.

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.

Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K.

Oncotarget. 2017 Feb 28;8(9):14897-14911. doi: 10.18632/oncotarget.14689.

41.

Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer.

Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez-MacGregor M, Yang WT.

Acad Radiol. 2017 Feb;24(2):191-199. doi: 10.1016/j.acra.2016.11.015. Epub 2016 Dec 7.

42.

Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy.

Hunt KK, Euhus DM, Boughey JC, Chagpar AB, Feldman SM, Hansen NM, Kulkarni SA, McCready DR, Mamounas EP, Wilke LG, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2017 Feb;24(2):375-397. doi: 10.1245/s10434-016-5688-z. Epub 2016 Dec 8. Review.

PMID:
27933411
43.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K.

Clin Cancer Res. 2017 Jun 15;23(12):2991-3002. doi: 10.1158/1078-0432.CCR-16-2217. Epub 2016 Nov 23.

44.

Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.

FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R.

Ann Surg Oncol. 2017 Mar;24(3):652-659. doi: 10.1245/s10434-016-5605-5. Epub 2016 Oct 3.

45.

Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.

Vila J, Teshome M, Tucker SL, Woodward WA, Chavez-MacGregor M, Hunt KK, Mittendorf EA.

Ann Surg. 2017 Mar;265(3):574-580. doi: 10.1097/SLA.0000000000001492.

PMID:
27735826
46.

Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.

Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, Chavez-Macgregor M, Hunt KK, Meric-Bernstam F, Woodward WA.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):637-44. doi: 10.1016/j.ijrobp.2016.07.003. Epub 2016 Jul 13.

PMID:
27681760
47.

Cost and Complications of Local Therapies for Early-Stage Breast Cancer.

Smith BD, Jiang J, Shih YC, Giordano SH, Huo J, Jagsi R, Momoh AO, Caudle AS, Hunt KK, Shaitelman SF, Buchholz TA, Shirvani SM.

J Natl Cancer Inst. 2016 Sep 27;109(1). pii: djw178. Print 2017 Jan.

PMID:
27678203
48.

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K.

Mol Cancer Res. 2017 Jan;15(1):45-58. doi: 10.1158/1541-7786.MCR-16-0157. Epub 2016 Sep 26.

49.

Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.

Chiba A, Hoskin TL, Heins CN, Hunt KK, Habermann EB, Boughey JC.

Ann Surg Oncol. 2017 Feb;24(2):418-424. doi: 10.1245/s10434-016-5585-5. Epub 2016 Sep 23.

50.

Considerations for the Treatment of Young Patients with Breast Cancer.

Menen RS, Hunt KK.

Breast J. 2016 Nov;22(6):667-672. doi: 10.1111/tbj.12644. Epub 2016 Aug 19. Review.

PMID:
27542172

Supplemental Content

Support Center